Gamma Biosciences Acquires BioMagnetic Solutions

GI Partners Completes Acquisition of Charles River’s CDMO and Cell Solutions Businesses, Forms Rose BioSolutions

May 8, 2026

Healthcare Services

GI Partners completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories, creating an independent advanced therapy manufacturing company, Rose BioSolutions. Rose BioSolutions will provide end-to-end cell and gene therapy development and manufacturing, covering plasmid DNA, viral vectors, cell therapy production, and cellular starting materials.

10x Genomics to Acquire Scale Biosciences

August 7, 2025

Healthcare Services

10x Genomics, Inc. has signed a definitive agreement to acquire Scale Biosciences, Inc., a single-cell analysis company. The deal is intended to expand 10x’s Chromium platform with Scale’s key inventions and technologies and broaden access to scalable single-cell analysis for researchers worldwide.

Cell Microsystems Acquires Fluxion Biosciences

August 23, 2023

Medical Devices

Durham-based Cell Microsystems has acquired Fluxion Biosciences, adding Fluxion's IonFlux, BioFlux and IsoFlux instruments and services to its CellRaft-based product portfolio. The deal is supported by a concurrent Series B financing led by Telegraph Hill Partners to provide growth capital and accelerate product and service integration for cellular analysis and electrophysiology workflows.

Syner-G BioPharma Group (Riverside Partners) Acquires RMC Pharmaceutical Solutions

January 24, 2023

Healthcare Services

Syner-G BioPharma Group, a portfolio company of Riverside Partners, has acquired RMC Pharmaceutical Solutions, an outsourced CMC and quality management services provider based in Colorado. The add-on strengthens Syner-G's pharmaceutical science capabilities—particularly biologics and cell & gene therapy development—by integrating RMC's process and analytical development, regulatory strategy, and quality management expertise.

CellCarta Acquires Biogazelle

December 14, 2021

Biotechnology

CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.